Thing Rinda. Soong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thing Rinda. Soong has a total of 226 co-authors. Here are the top co-authors by number of shared publications:
- Holly R. Harris
Public Health Sciences Division, Fred Hutchinson Cancer Center , Seattle, WA
82 shared publications - Jennifer Anne Doherty
Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
82 shared publications - Esther Elishaev
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA
79 shared publications - Francesmary Modugno
Department of Obstetrics, Gynecology, and Reproductive Sciences University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA
79 shared publications - Adelyn Bolithon
School of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, Australia. 4
73 shared publications - Ahwan Pandey
Peter MacCallum Cancer Centre, Melbourne, Australia
73 shared publications
Latest Publications
- 2 April 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (7) , 1537-1539
Not All STICs Are Equal: Unraveling the Implications of Precursor Heterogeneity
Serous tubal intraepithelial carcinomas (STIC) are precursors of high-grade serous carcinoma (HGSC), the deadliest subtype of ovarian carcinoma. To establish clinically actionable strategies against these lesions, a better understanding of the mutational, transcriptional, and genetic/epigenetic alterations, as well as interactions among epithelial, immune, and stromal cells, is essential. In this issue of Cancer Research, Shih and colleagues conducted the first integrated spatial multiomics analysis of ovarian precancerous lesions, revealing substantial heterogeneity within the fallopian tube epithelium that may influence cancer susceptibility. They described four molecular subclasses of STICs according to their epithelial transcriptomic profiles: proliferative, immunoreactive, mixed, and dormant (PIMD) subtypes. Molecular links of this “PIMD” STIC subclassification to tumor progression were proposed, uncovering early events in ovarian tumorigenesis and potential genetic drivers of STIC heterogeneity. Furthermore, the STIC subtypes showed distinct histologic and molecular characteristics that warrant further investigation to develop a deeper understanding of the molecular and cellular processes driving the evolution of STIC heterogeneity, which may facilitate the development of early diagnostic approaches for HGSC. Collectively, the findings that not all STICs are equal open new avenues for further clinicopathologic, translational, and basic research to improve risk classification and early intervention in HGSC. See related article by Chang et al., p. 1739
- 2 April 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (7) , 1537-1539
Not All STICs Are Equal: Unraveling the Implications of Precursor Heterogeneity
Serous tubal intraepithelial carcinomas (STIC) are precursors of high-grade serous carcinoma (HGSC), the deadliest subtype of ovarian carcinoma. To establish clinically actionable strategies against these lesions, a better understanding of the mutational, transcriptional, and genetic/epigenetic alterations, as well as interactions among epithelial, immune, and stromal cells, is essential. In this issue of Cancer Research, Shih and colleagues conducted the first integrated spatial multiomics analysis of ovarian precancerous lesions, revealing substantial heterogeneity within the fallopian tube epithelium that may influence cancer susceptibility. They described four molecular subclasses of STICs according to their epithelial transcriptomic profiles: proliferative, immunoreactive, mixed, and dormant (PIMD) subtypes. Molecular links of this “PIMD” STIC subclassification to tumor progression were proposed, uncovering early events in ovarian tumorigenesis and potential genetic drivers of STIC heterogeneity. Furthermore, the STIC subtypes showed distinct histologic and molecular characteristics that warrant further investigation to develop a deeper understanding of the molecular and cellular processes driving the evolution of STIC heterogeneity, which may facilitate the development of early diagnostic approaches for HGSC. Collectively, the findings that not all STICs are equal open new avenues for further clinicopathologic, translational, and basic research to improve risk classification and early intervention in HGSC. See related article by Chang et al., p. 1739
- 10 March 2026
- Published by Wiley in Histopathology
- Vol. 89 (1) , 154-162
Assessment of lymphovascular space invasion in cervical squamous cell carcinoma using digital pathology: a reproducibility study
Introduction and aims: Lymphovascular space invasion (LVSI) is associated with increased nodal involvement and disease recurrence in cervical squamous cell carcinoma (SCC). While LVSI is currently included in some clinical risk assessment algorithms, the reproducibility of diagnosing LVSI remains understudied in cervical SCC. We aimed to assess the inter‐observer agreement for LVSI diagnosis using digital whole slide images (WSIs) of haematoxylin and eosin‐stained (H&E) slides with presumed true LVSI ( n = 20) and LVSI mimics ( n = 20) from early‐stage cervical SCC identified in an international cohort. Methods and results: The reference diagnosis for LVSI status was established by 2 pathologists through consensus review. Ten independent pathologists from North and South America, Europe, Asia and South Africa were included for blinded scoring of true LVSI versus LVSI mimics. Complete concordance was seen in 57% of cases. Overall percent agreement was 88% with the κ value being 0.76, reflecting substantial agreement on LVSI diagnosis based on H&E WSIs. Conclusions: Our findings support the diagnostic feasibility and reliability of including LVSI as a parameter in routine histologic evaluation for risk stratification of cervical SCC. While the inter‐observer agreement in our study is acceptable, there remains a need for standardised diagnostic criteria and guidance on the use of immunohistochemical studies for the detection or confirmation of LVSI in daily practice.
- 10 March 2026
- Published by Wiley in Histopathology
- Vol. 89 (1) , 154-162
Assessment of lymphovascular space invasion in cervical squamous cell carcinoma using digital pathology: a reproducibility study
Introduction and aims: Lymphovascular space invasion (LVSI) is associated with increased nodal involvement and disease recurrence in cervical squamous cell carcinoma (SCC). While LVSI is currently included in some clinical risk assessment algorithms, the reproducibility of diagnosing LVSI remains understudied in cervical SCC. We aimed to assess the inter‐observer agreement for LVSI diagnosis using digital whole slide images (WSIs) of haematoxylin and eosin‐stained (H&E) slides with presumed true LVSI ( n = 20) and LVSI mimics ( n = 20) from early‐stage cervical SCC identified in an international cohort. Methods and results: The reference diagnosis for LVSI status was established by 2 pathologists through consensus review. Ten independent pathologists from North and South America, Europe, Asia and South Africa were included for blinded scoring of true LVSI versus LVSI mimics. Complete concordance was seen in 57% of cases. Overall percent agreement was 88% with the κ value being 0.76, reflecting substantial agreement on LVSI diagnosis based on H&E WSIs. Conclusions: Our findings support the diagnostic feasibility and reliability of including LVSI as a parameter in routine histologic evaluation for risk stratification of cervical SCC. While the inter‐observer agreement in our study is acceptable, there remains a need for standardised diagnostic criteria and guidance on the use of immunohistochemical studies for the detection or confirmation of LVSI in daily practice.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Endometriosis-Associated Mesenchymal Stem Cells Support Ovarian Clear Cell Carcinoma through Iron Regulation
Supplementary figures and table
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Endometriosis-Associated Mesenchymal Stem Cells Support Ovarian Clear Cell Carcinoma through Iron Regulation
Supplementary figures and table
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Endometriosis-Associated Mesenchymal Stem Cells Support Ovarian Clear Cell Carcinoma through Iron Regulation
Ovarian clear cell carcinoma (OCCC) is a deadly and treatment-resistant cancer, which arises within the unique microenvironment of endometriosis. In this study, we identified a subset of endometriosis-derived mesenchymal stem cells (enMSC) characterized by loss of CD10 expression that specifically support OCCC growth. RNA sequencing identified alterations in iron export in CD10-negative enMSCs and reciprocal changes in metal transport in cocultured OCCC cells. CD10-negative enMSCs exhibited elevated expression of iron export proteins hephaestin and ferroportin and donate iron to associated OCCCs, functionally increasing the levels of labile intracellular iron. Iron is necessary for OCCC growth, and CD10-negative enMSCs prevented the growth inhibitory effects of iron chelation. In addition, enMSC-mediated increases in OCCC iron resulted in a unique sensitivity to ferroptosis. In vitro and in vivo, treatment with the ferroptosis inducer erastin resulted in significant death of cancer cells grown with CD10-negative enMSCs. Collectively, this work describes a novel mechanism of stromal-mediated tumor support via iron donation. This work also defines an important role of endometriosis-associated MSCs in supporting OCCC growth and identifies a critical therapeutic vulnerability of OCCC to ferroptosis based on stromal phenotype.Significance:Endometriosis-derived mesenchymal stem cells support ovarian clear cell carcinoma via iron donation necessary for cancer growth, which also confers sensitivity to ferroptosis-inducing therapy.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Endometriosis-Associated Mesenchymal Stem Cells Support Ovarian Clear Cell Carcinoma through Iron Regulation
Ovarian clear cell carcinoma (OCCC) is a deadly and treatment-resistant cancer, which arises within the unique microenvironment of endometriosis. In this study, we identified a subset of endometriosis-derived mesenchymal stem cells (enMSC) characterized by loss of CD10 expression that specifically support OCCC growth. RNA sequencing identified alterations in iron export in CD10-negative enMSCs and reciprocal changes in metal transport in cocultured OCCC cells. CD10-negative enMSCs exhibited elevated expression of iron export proteins hephaestin and ferroportin and donate iron to associated OCCCs, functionally increasing the levels of labile intracellular iron. Iron is necessary for OCCC growth, and CD10-negative enMSCs prevented the growth inhibitory effects of iron chelation. In addition, enMSC-mediated increases in OCCC iron resulted in a unique sensitivity to ferroptosis. In vitro and in vivo, treatment with the ferroptosis inducer erastin resulted in significant death of cancer cells grown with CD10-negative enMSCs. Collectively, this work describes a novel mechanism of stromal-mediated tumor support via iron donation. This work also defines an important role of endometriosis-associated MSCs in supporting OCCC growth and identifies a critical therapeutic vulnerability of OCCC to ferroptosis based on stromal phenotype.Significance:Endometriosis-derived mesenchymal stem cells support ovarian clear cell carcinoma via iron donation necessary for cancer growth, which also confers sensitivity to ferroptosis-inducing therapy.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supplementary Table 1 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supplementary Table 1 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supp. Figure 2 A) Unmodified principal component analysis. B) WT1 MFI in CA-MSCs and nMSCs. The lower limit of CA-MSC WT1 MFI was used to classify hrMSCs. C) Proliferation assay (full time course) using ovarian cancer cells and shRNA knockdown MSCs. Scramble shRNA and tumor cells alone are shown. D) Tissue culture treated plates were coated with poly-D-lysine. This served as a positive control for adherence assays. FT190 control cells and OVSAHO tumor cells were utilized. P-values are shown. P-values were determined by Student’s T-test.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supp. Figure 2 A) Unmodified principal component analysis. B) WT1 MFI in CA-MSCs and nMSCs. The lower limit of CA-MSC WT1 MFI was used to classify hrMSCs. C) Proliferation assay (full time course) using ovarian cancer cells and shRNA knockdown MSCs. Scramble shRNA and tumor cells alone are shown. D) Tissue culture treated plates were coated with poly-D-lysine. This served as a positive control for adherence assays. FT190 control cells and OVSAHO tumor cells were utilized. P-values are shown. P-values were determined by Student’s T-test.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supplementary data AMPK related DEG list
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supplementary data AMPK related DEG list
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supp. Figure 4 A) Representative images of organoids that were injected into NSG mice. FTE and MSCs were seeded at a 1:1 ratio under non-adherent conditions. FTE are labelled in red while hrMSCs are labelled in blue.B) Representative image of pancytokeratin IHC of tumor resulting from organoid implanted in vivo demonstrating human epithelial origin.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supp. Figure 4 A) Representative images of organoids that were injected into NSG mice. FTE and MSCs were seeded at a 1:1 ratio under non-adherent conditions. FTE are labelled in red while hrMSCs are labelled in blue.B) Representative image of pancytokeratin IHC of tumor resulting from organoid implanted in vivo demonstrating human epithelial origin.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supp. Figure 6 A) MDA adduct ELISA comparing nMSC and hrMSC conditioned media. Individual data points represent individual patient cell lines. Statistics were determined by the student’s T-test. B) Western blot validation of GW4969 effect on MSCs. Conditioned media was ultracentrifuged to remove large EVs (>500 µm) and exosomes (<500 µm). EV lysates were probed for CD36 expression. C) IF validation of EV transfer. MSCs were labelled with BODIPY C-12 and media was collected after an overnight incubation. Media was spun to remove debris and added to epithelial cells. Epithelial cells were screened for BODIPY positivity. D) MSCs were stained with BODIPY C-12, allowed to rest for 1hr, then media was removed, spun to remove debris, and added to FTE. FTE were analyzed by flow cytometry for BODIPY C-12 positivity. P-values are shown. P-values were determined by the student’s t-test.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supp. Figure 6 A) MDA adduct ELISA comparing nMSC and hrMSC conditioned media. Individual data points represent individual patient cell lines. Statistics were determined by the student’s T-test. B) Western blot validation of GW4969 effect on MSCs. Conditioned media was ultracentrifuged to remove large EVs (>500 µm) and exosomes (<500 µm). EV lysates were probed for CD36 expression. C) IF validation of EV transfer. MSCs were labelled with BODIPY C-12 and media was collected after an overnight incubation. Media was spun to remove debris and added to epithelial cells. Epithelial cells were screened for BODIPY positivity. D) MSCs were stained with BODIPY C-12, allowed to rest for 1hr, then media was removed, spun to remove debris, and added to FTE. FTE were analyzed by flow cytometry for BODIPY C-12 positivity. P-values are shown. P-values were determined by the student’s t-test.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supp. Figure 3 A/B/C) gH2AX and 53BP1 foci in cell trace deep red labelled MSCs. MSCs were co-cultured with FTE at a 1:1 ratio. D) Representative image of stromal regions that were chosen for 53BP1 foci validation in patient samples. Yellow X represents nMSCs while red X represents hrMSCs. E) Representative phenotype masking and 53BP1 stain in patient fallopian tubes. Foci were identified using ImageJ and are indicated as magenta foci in Fig. 3H. Cells that lacked clear foci, including cells without signal, were considered negative for 53BP1 foci. P-values are shown. P-values were determined by Student’s T-test.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supp. Figure 3 A/B/C) gH2AX and 53BP1 foci in cell trace deep red labelled MSCs. MSCs were co-cultured with FTE at a 1:1 ratio. D) Representative image of stromal regions that were chosen for 53BP1 foci validation in patient samples. Yellow X represents nMSCs while red X represents hrMSCs. E) Representative phenotype masking and 53BP1 stain in patient fallopian tubes. Foci were identified using ImageJ and are indicated as magenta foci in Fig. 3H. Cells that lacked clear foci, including cells without signal, were considered negative for 53BP1 foci. P-values are shown. P-values were determined by Student’s T-test.